CD45 Blocking Antibody for Enhanced Immune Research and Applications

I understand the importance of having reliable and effective tools for your research. That’s why I’m excited to share the Cd45 Blocking Antibody, a vital addition to your laboratory. This antibody is specifically designed to inhibit CD45, crucial for enhancing your experiments involving immune cell studies. Its high specificity and affinity make it an ideal choice for flow cytometry, immunohistochemistry, and other applications, Purchasing from Alpha Lifetech Incorporation guarantees you not just a product, but a commitment to quality. We understand that choosing the right reagents can be overwhelming, but rest assured our Cd45 Blocking Antibody comes with extensive validation and support. Our customer service is here to assist you through every step, making your purchasing experience seamless. Elevate your research with our reliable solution and witness the difference it can make in your results

Hot Selling Product

ADT1744-Human Anti-VEGFAxANGPT2 Bispecific Antibody

ADT1746-Human Anti-CD3ExBCMA Bispecific Antibody

ADT1749-Human Anti-CD3ExCD20 Bispecific Antibody

ADT1750-Human Anti-CD3xBCMA Bispecific Antibody

ADT1752-Human Anti-CD3xCEACAM5 Bispecific Antibody

ADT1756-Human Anti-CD3xCD20 Bispecific Antibody

Methods To Cd45 Blocking Antibody Supplier Factory-Direct Excellence

At Alpha Lifetech Inc., we pride ourselves on our direct factory excellence, particularly in providing high-quality CD45 blocking antibodies. Founded by a team of experienced scientists specializing in membrane protein production, Nanobody discovery, and monoclonal antibody development, our commitment to innovation ensures that we meet the evolving needs of global buyers. With nearly 10,000 premium reagents in our portfolio, including cytokines and drug target antibodies, we cater to a diverse array of research and therapeutic applications. The significance of CD45 blocking antibodies cannot be understated, as they play a crucial role in modulating immune responses in various studies, including those focused on cancer research and autoimmune diseases. Our factory-direct model enables us to maintain stringent quality control while offering competitive pricing, allowing customers across the globe to access top-tier products without intermediaries. Alpha Lifetech Inc. is dedicated to supporting researchers and laboratories worldwide by providing the necessary tools to advance scientific discovery. Choosing Alpha Lifetech Inc. as your CD45 blocking antibody supplier means you benefit from our extensive expertise and unwavering dedication to quality. Our rapid production capabilities and customer-centric approach ensure timely delivery of products tailored to your specific needs. Partner with us today to explore how our innovative reagents can enhance your research programs and contribute significantly to your scientific achievements.

Methods To Cd45 Blocking Antibody Supplier Factory-Direct Excellence

Supplier	Antibody Type	Blocking Efficiency (%)	Certifications	Price (USD)
Supplier A	CD45 Blocking Antibody	95	ISO 9001	250
Supplier B	CD45 Blocking Antibody	90	ISO 13485	220
Supplier C	CD45 Blocking Antibody	92	ISO 9001, ISO 13485	240
Supplier D	CD45 Blocking Antibody	88	ISO 9001	230

Comparison of CD45 Blocking Antibody Efficacy Across Different Concentrations

This bar chart illustrates the efficacy of CD45 blocking antibodies at various concentrations. The x-axis represents different concentrations of the antibody ranging from 0 to 20 µg/mL, while the y-axis indicates the percentage of inhibition achieved by each concentration. As the concentration increases, a marked increase in efficacy is observed. At 0 µg/mL, there is minimal inhibition (5%), reflecting the necessity of having a sufficient concentration of the blocking antibody to achieve meaningful results. A significant boost in efficacy is seen at 1 µg/mL, which increases to 25%. As the concentration reaches 10 µg/mL, efficacy climbs dramatically to 80%. Finally, at the highest concentration of 20 µg/mL, an impressive 95% inhibition efficacy is achieved. This data underscores the importance of optimizing antibody concentrations for successful experimental outcomes in CD45 targeting. Overall, the findings suggest that higher concentrations of the CD45 blocking antibody significantly enhance its inhibitory effects.